Mads Krogsgaard Thomsen/LinkedIn
Dec 16, 2025, 16:34
Mads Krogsgaard Thomsen on Novo Nordisk Haemophilia Foundation’s Support for Haemoglobinopathies
Mads Krogsgaard Thomsen, CEO at Novo Nordisk Foundation, shared on LinkedIn:
”Haemophilia and other blood disorders like sickle cell disease and thalasaemia are chronic, debilitating diseases.
As is often the case, global health inequity is very pronounced, with under-diagnosis, under-treament and poor outcomes as a result in many low and middle income countries.
It is therefore a pleasure to announce that Novo Nordisk Foundation is stepping up, both in absolute funding terms, and in adding the haemoglobinopathy disorders to our support to the Novo Nordisk Haemophilia and Haemoglobinopathies Foundation in these areas.”
Read the full announcement here.
Stay updated with Hemostasis Today.
-
Mar 16, 2026, 16:08Deepak Sudheendra: When a Vascular Looking Skin Pattern Isn’t Vascular
-
Mar 16, 2026, 16:06Surendra Karki։ Examining Blood Type and Coronary Heart Disease Risk in Australian Donors
-
Mar 16, 2026, 15:58Alan Nurden: Genome-Wide Analyses Unravel the Genetic Architecture of Coagulation and Fibrinolysis
-
Mar 16, 2026, 15:56Emmanuel J. Favaloro: Latest Publication from Sydney Centres on Heparin Therapy and Monitoring
-
Mar 16, 2026, 15:53Suvro Sankha Datta: Reporting Auto-Anti-Jk Antibodies in Children with Hematological Disorders
-
Mar 16, 2026, 15:44Francis Kynaston-Pearson: Why Randomised Controlled Trials Are the Gold Standard in Clinical Research
-
Mar 16, 2026, 15:18Kalpana Gupta Shekhawat: A Practical Clinical Approach to Iron Regulation
-
Mar 16, 2026, 15:08Mohamed Sikkander Abdul Razak: Warning Signs of Vitamin Deficiencies
-
Mar 16, 2026, 15:05Kate Thomas: Plasma Donations Drive New Era of Life-Saving Medicines in the UK